Infectious Disease and Microbiology – Burkholderia pseudomallei

Overview

Burkholderia pseudomallei is an aerobic Gram-negative bacillus that causes melioidosis, an infection that may remain localized or progress to pneumonia, bacteremia, sepsis, and multiple internal abscesses. The organism is closely associated with soil and surface water in endemic tropical regions.

Melioidosis is especially important because it can present either shortly after exposure or after a prolonged latent period.

Microbiologic Characteristics

B. pseudomallei is:

• Gram negative

• Bacillary

• Aerobic

• An environmental saprophyte

It can survive in soil and water and is well adapted to tropical environments.

Incubation Period

The incubation period is highly variable.

Some patients develop symptoms within only:

2–3 days

However, infection can also remain latent, with disease emerging:

Months or even years later

This delayed presentation is a classic feature of melioidosis.

Epidemiology

B. pseudomallei is found naturally in:

• Soil

• Mud

• Surface water

• Ponds

• Contaminated environmental material

Melioidosis is especially important in Southeast Asia and northern Australia, with Thailand historically representing one of the major endemic regions.

In highly endemic areas, it can account for a substantial proportion of community-acquired sepsis.

Transmission

Humans most commonly acquire infection through environmental exposure.

Important routes include:

• Inoculation of contaminated soil or water into cuts and abrasions

• Inhalation of contaminated dust or aerosols

• Aspiration or ingestion of contaminated water

Direct person-to-person transmission is extremely uncommon.

Risk Factors

Severe melioidosis is particularly associated with:

• Diabetes mellitus

• Chronic kidney disease

• Heavy alcohol use

• Chronic lung disease

• Immunosuppression

• Older age

Diabetes is one of the strongest recognized risk factors.

Clinical Manifestations

Melioidosis has a remarkably broad clinical spectrum.

It may present as:

• Localized skin infection

• Lymphadenitis

• Pneumonia

• Bacteremia

• Sepsis

• Disseminated infection with multiple abscesses

Localized Skin Disease

Inoculation through broken skin may produce:

• Papules

• Pustules

• Ulcers

• Abscesses

• Regional lymphadenitis

Localized infection can remain limited or progress hematogenously.

Pneumonia

Pneumonia is one of the most important forms of melioidosis.

Symptoms may include:

• Fever

• Cough

• Sputum production

• Dyspnea

• Pleuritic chest pain

• Hemoptysis in severe disease

Radiographic appearances can resemble bacterial pneumonia, tuberculosis, or lung abscess.

Bacteremia and Sepsis

Severe disease can produce:

• High fever

• Hypotension

• Septic shock

• Multiorgan dysfunction

• High mortality if treatment is delayed

Melioidosis should be considered in a patient from an endemic region with community-acquired sepsis and no obvious source.

Disseminated Abscesses

One of the classic features of systemic melioidosis is the formation of abscesses in multiple organs.

Potential sites include:

• Liver

• Spleen

• Prostate

• Kidney

• Bone

• Brain

• Soft tissues

A characteristic radiologic pattern of multiple small abscesses in the liver and spleen is sometimes described as a “honeycomb” appearance.

Neurologic Disease

Neurologic melioidosis is less common but serious.

Possible manifestations include:

• Brainstem encephalitis

• Cranial nerve abnormalities

• Weakness

• Ataxia

• Meningitis

• Brain abscess

These cases require prolonged therapy and careful specialist management.

Bone and Joint Disease

Melioidosis may cause:

• Osteomyelitis

• Septic arthritis

Persistent focal pain or swelling should prompt imaging and assessment for deep infection.

Diagnosis

Culture

The definitive diagnosis is usually made by culture of B. pseudomallei from:

• Blood

• Sputum

• Pus

• Urine

• Abscess fluid

• Other sterile-site specimens

Because the organism has important laboratory biosafety implications, the microbiology laboratory should be informed when melioidosis is suspected.

Serology

Serologic testing may provide supportive information in endemic areas, but its specificity can be limited because background antibody positivity may occur.

A positive antibody test alone does not establish active disease.

Molecular and Antigen Detection

In endemic regions, locally developed molecular or antigen-detection methods may support diagnosis.

PCR can be useful where available, particularly in difficult or rapidly progressive cases.

Treatment

Management has two distinct phases:

1. Intensive therapy

followed by

2. Eradication therapy

Both phases are essential because relapse can occur if treatment is stopped too early.

Intensive Phase

For severe melioidosis, the source lists:

Ceftazidime 2 g IV every 6 hours

or

Meropenem 1 g IV every 8 hours

or

Imipenem 1 g IV every 6 hours

for at least:

10–14 days

Longer intensive treatment may be required for deep-seated or complicated disease.

Role of TMP-SMX

Trimethoprim-sulfamethoxazole may be added, especially when there is:

• Neurologic disease

• Cutaneous disease

• Bone infection

• Prostatic infection

This is particularly important because tissue penetration and eradication of residual organisms are critical in these sites.

Eradication Phase

After the intensive phase, prolonged oral therapy is required.

The classic regimen is:

TMP-SMX orally for at least 3 months

This phase reduces the risk of relapse.

Older regimens sometimes combined TMP-SMX with doxycycline, though current practice often favors TMP-SMX alone when tolerated and active.

Abscess Drainage

Large abscesses may require:

• Percutaneous drainage

• Surgical drainage

• Debridement when necessary

Source control is particularly important for large or poorly responding collections.

Additional Treatment Options

Amoxicillin-clavulanate can sometimes be used as an alternative when first-line oral eradication therapy cannot be used.

Fluoroquinolones have historically been considered, but they are generally less reliable and are not preferred when more effective agents are available.

Antimicrobial Resistance

Susceptibility patterns vary.

A notable concern is resistance to TMP-SMX in some isolates, particularly in regions where resistance has historically been reported.

For this reason, serious infections should be managed according to current susceptibility testing whenever possible.

Prevention

There is no widely available human vaccine.

Risk reduction includes:

• Avoiding direct contact with soil or muddy water when skin is broken

• Wearing protective footwear and gloves in endemic areas

• Covering cuts and abrasions

• Avoiding exposure to contaminated surface water, particularly in high-risk individuals

• Using safe water practices during severe weather and flooding

People with diabetes or other major risk factors should be particularly cautious in endemic areas.

High-Yield Clinical Pattern

Endemic-area exposure

• ●

Diabetes

• ●

Community-acquired pneumonia or sepsis

• ●

Multiple internal abscesses

→ Think melioidosis due to Burkholderia pseudomallei

High-Yield Treatment Pattern

Severe melioidosis:

→ Ceftazidime or a carbapenem

then

→ Prolonged TMP-SMX eradication therapy

Exam Essentials

Organism:

→ Burkholderia pseudomallei

Microbiology:

→ Aerobic Gram-negative bacillus

Disease:

→ Melioidosis

Reservoir:

→ Soil and surface water

Major geographic association:

→ Southeast Asia and northern Australia

Incubation:

→ Days to years

Important risk factor:

→ Diabetes mellitus

Major clinical forms:

→ Skin infection, pneumonia, bacteremia, sepsis, disseminated abscesses

Diagnosis:

→ Culture

Initial intensive treatment:

→ Ceftazidime, meropenem, or imipenem

Eradication treatment:

→ Prolonged TMP-SMX

Important additional management:

→ Drain large abscesses

Major clinical pearl:

→ Melioidosis can relapse or present long after the initial environmental exposure, so both adequate intensive therapy and prolonged eradication therapy are essential.